Roche's Tecentriq notches win in breast cancer with U.S. approval

Roche won U.S. approval on Friday of its immunotherapy Tecentriq to treat a significant number of patients with triple-negative breast cancer, a development hailed by doctors as a promising advance in fighting the aggressive disease.